Silent airways and targeted relief: Avanos ON-Q pump stays in focus after opioid shift

Avanos’ ON-Q Pain Relief System is aimed at keeping post-surgical patients more comfortable while helping hospitals cut back on opioids. We look at how the elastomeric pump works, where it fits in multimodal pain management, and why it remains a key product in Avanos’ medical portfolio.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 10:15 AM ET. Details in the imprint.

The ON-Q Pain Relief System from Avanos has become a quiet workhorse in post-surgical care, delivering continuous local anesthetic directly to the surgical site through a small, balloon-like pump designed to minimize the need for systemic opioids. According to Avanos, the single-use elastomeric pump lets clinicians program a continuous flow of local anesthetic over several days, with the goal of keeping patients more comfortable during the most painful phase after surgery. The official product information describes ON-Q as a portable pump that can deliver local anesthetic for up to five days.

How the ON-Q pump works inside modern pain protocols

At its core, ON-Q is an elastomeric, non-electronic pump that slowly squeezes a reservoir of local anesthetic through thin catheters placed by the surgeon near nerves or the incision, allowing the anesthetic to bathe the tissues continuously. This stands in contrast to single-shot nerve blocks that wear off within hours, forcing patients to rely more heavily on oral or intravenous painkillers once the initial block fades. The system is available in multiple reservoir volumes and fixed flow rates, so hospitals can match pump size and duration to common procedures such as orthopedic joint replacements, abdominal surgeries or C-section incisions.

Avanos emphasizes that ON-Q is intended to support multimodal analgesia strategies, in which local anesthetics, non-opioid analgesics and limited opioids are combined to control pain while mitigating side effects and dependency risks. In practice, that means patients may receive scheduled doses of acetaminophen or NSAIDs alongside the continuous local anesthetic infusion, and resort to opioids only when pain spikes beyond a certain threshold. For ambulatory surgery centers, the portability of the balloon pump is particularly important: patients can be discharged home with the device and educated on basic precautions, then have the catheter removed by their provider after the infusion period ends.

Because ON-Q relies on passive pressure rather than electronics, it does not require batteries or active programming on a screen, which simplifies training and helps avoid some alarm fatigue issues associated with electronic infusion pumps. Nurses typically monitor the device by visually checking the balloon reservoir, assessing pain scores and confirming that the flow restrictor and catheter lines remain intact and free of kinks. The system also includes filter components and connectors designed to reduce the risk of contamination during setup, since the pump itself is a sterile, single-use product supplied from the factory.

In the context of the US opioid epidemic, products like ON-Q have been promoted as tools that can reduce opioid consumption in the immediate postoperative period. Avanos has cited clinical studies showing reductions in opioid use and improvements in patient satisfaction when continuous local anesthetic infusions are used compared with opioid-heavy regimens, though the exact magnitude of benefit can vary based on procedure type and protocol design. For hospital administrators, this positions ON-Q as one component of broader enhanced recovery after surgery (ERAS) programs that seek to shorten length of stay and improve patient-reported outcomes while meeting internal targets on opioid stewardship.

From a practical standpoint, ON-Q competes with other elastomeric and electronic infusion solutions that also deliver local anesthetics or analgesics, as well as with more traditional strategies centered on systemic medications. Clinicians weigh device cost, reliability, ease of use, and the ability to tailor dosing when selecting a system, while payers and procurement teams scrutinize whether reduced opioid use and potential shorter stays offset the per-case device expense. In orthopedics, for example, some centers have moved toward adductor canal or pericapsular nerve group blocks combined with continuous infusions, while others favor single-shot blocks and aggressive oral regimens, keeping the competitive landscape fluid.

Beyond general surgical use, ON-Q has also been positioned in specific pathways such as labor and delivery, cesarean sections and pediatric procedures, where the desire to limit opioid exposure is particularly pronounced. According to product literature and clinical pathway descriptions, some institutions integrate ON-Q into standardized order sets for knee or shoulder surgeries, embedding the device into routine workflows rather than reserving it for unusual or high-risk cases. That kind of protocol-level integration tends to be a key determinant of sustained adoption, as it reduces reliance on individual clinician preference and ensures that nursing teams know what to expect from case to case.

Avanos itself has been reshaping its portfolio around areas like pain management, digestive health and respiratory health, and ON-Q continues to sit in the center of its regional anesthesia lineup. The company notes that ON-Q has been on the market for years, benefiting from iterative updates rather than a single headline-grabbing launch, which helps explain why many clinicians view it as a familiar, established tool rather than a brand-new technology. At the same time, regulatory expectations and safety standards for infusion devices have evolved, requiring manufacturers to maintain vigilance on labeling, training materials and post-market surveillance.

Strategically, persistent demand for post-surgical pain solutions gives Avanos an incentive to keep investing in ON-Q and adjacent technologies, even as competition and pricing pressure remain. For retail investors, ON-Q is one of several products that anchor the company’s pain management segment, which Avanos has identified as a focus area in recent strategy updates and earnings discussions. Shares of Avanos Medical (ISIN US05350V1061) traded on the NYSE at $20.61 on 06/13/2026, reflecting the market’s evolving view of its diversified medical-device portfolio. In a recent investor presentation, Avanos highlighted ON-Q among its key legacy pain-management platforms.

ON-Q Pain Relief System in brief: key specifications

• Product: ON-Q Pain Relief System
• Manufacturer: Avanos Medical, Inc.
• Category: Flagship postoperative pain management device
• Launch date: Initially introduced in the 2000s, with ongoing updates
• MSRP / Price: Contract-based hospital pricing; single-use pump typically supplied per procedure
• Availability: Hospital and ambulatory surgery center channels in the US and selected international markets
• Target audience: Surgeons, anesthesiologists and pain teams managing post-surgical patients
• Key differentiator / USP: Non-electronic elastomeric pump delivering continuous local anesthetic to reduce reliance on systemic opioids

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.